Puma Biotechnology Inc — Earnings Quality Grade C
PBYI · Healthcare
Some red flags
Screening Summary
Management Signals
Financial Trends
Revenue & Net Income ($B)
Margins (%)
18-Point Screening
Revenue Quality
DSO surged by 35 days (51 → 86)
Small-cap context: DSO swings on a small revenue base are more often quarterly customer-mix effects than red flags.
AR growth 67.6% exceeds revenue growth -0.9%
Revenue -0.9%, CFFO 7.4%. Cash follows revenue
Expense Quality
Inventory -36.8% vs COGS -9.7%. Normal
CapEx growth 26.8% is >2x revenue growth -0.9%
SG&A/Gross Profit = 41.8%. Normal
Gross margin 74.5%, change +2.5pp. Stable
Cash Flow Quality
CFFO/NI = 1.34. Profits backed by cash
FCF $0.0B, FCF/NI = 1.34
Accruals ratio = -4.9%. Low accruals
Cash $0.1B covers debt $0.0B
Balance Sheet Health
Goodwill+Intangibles $0.0B = 32% of equity
Debt/EBITDA = 0.5x. Healthy
Other assets grew 20.2% vs revenue -0.9%
No write-off data
Acquisition Risk
FCF after acquisitions positive
Goodwill+Intangibles change -19% YoY. Normal
Manipulation Score
M-Score = -2.06 (grey zone)
Portfolio monitoring
Monitor PBYI continuously
The full checks and model details are free to read. Use Watchlist to track your holdings; Pro adds automatic quarterly rescoring, risk-event email alerts, scans up to 50 tickers, and export workflows.
Beneish M-Score
Altman Z-Score
Generated from public financial data using forensic accounting frameworks. Not investment advice. Data: Yahoo Finance · 2026-04-25